Monitoring therapy with gene expression profiling reveals physiological differences in drug action

作者：Wolfl S^*; Burchert A; Kroll TC

来源：Current Pharmaceutical Design, 2004, 10(16): 1959-1968.

DOI：10.2174/1381612043384385

• gene expression profiling
• tyrosine kinase inhibitor
• imatinib-mesylate
• IFN alpha
• therapy monitoring
• myeloblastin
• CML
• individualized medicine
• prognosis

Gene expression profiling has become a versatile tool for biomedical research, which allows the assessment of a wide variety of basic questions in cellular regulation, in particular when a large number of molecular parameters have changed. There are various applications in drug research for which gene expression profiling is a very suitable approach. This includes: target identification, target validation, validation of drug specificity and monitoring of drug action during therapy. The focus of this article is the therapy monitoring and the interpretation of the gene expression profiles in respect to physiological differences of drug action. As an example, we will discuss changes in gene expression in blood samples from CML patients treated with the tyrosine kinase inhibitor (imatinib mesylate) and compare the observed effects on gene expression with the effects of IFNalpha treatment. In comparison with other examples of therapy monitoring the potential of this application of gene expression profiling for optimizing individual therapy will be discussed.

• 出版日期2004